Hormone replacement therapy in gynecologic cancer survivors: Why not?

Ibeanu, Okechukwu A.; Modesitt, Susan C.; Ducie, J.A.; Gruenigen, Vivian von; Agueh, Modupe; Fader, Amanda N.

doi:10.1016/j.ygyno.2011.03.012

Cited by 43 publications

(37 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Women who have undergone premature ovarian failure (POF) due to oncological treatment are subject to a sudden onset of menopause which is often more severe than physiological menopause [3], with the onset of symptoms within days of surgery and within 12 weeks after starting radiotherapy. The stress of undergoing a cancer diagnosis can also cause menopausal symptoms to become more severe [4].…”

Section: Premature Ovarian Failurementioning

confidence: 99%

Iatrogenic Menopause After Treatment for Cervical Cancer

et al. 2016

View full text Add to dashboard Cite

Section: Premature Ovarian Failurementioning

confidence: 99%

Iatrogenic Menopause After Treatment for Cervical Cancer

et al. 2016

View full text Add to dashboard Cite

“…На сьогоднішній день для жінок, які перенесли рак молочної залози, ризики, пов'язані з МГТ, пе-ревищують користь. Пацієнтка повинна бути інформована про ризики пролонгації хвороби і рецидивів, пов'язаних з використанням МГТ [71].…”

Section: менеджмент менопаузи в жінок із онкологічною патологіею в анunclassified

National consensus on the management of patients in menopause

Вільєрс¹,

Татарчук²,

Avramenko³

et al. 2016

Reproductive Endocrinology

View full text Add to dashboard Cite

“…If contralateral ovary is normal, salpingo-oophorectomy of the ovary is recommended, and if her contralateral ovary was removed in a previous surgery, cystectomy is recommended. Conservative surgery is recommended only when invasive implants are absent, and patient is younger than 40 and also longterm and careful follow-up is possible (53,54). Questions not sufficiently covered by literature, but covered by expert opinion as follows:…”

Section: Recurrence Of Diseasementioning

confidence: 99%

Diagnosis and Management of Borderline Ovarian Tumor Based on the Iranian Guidelines

Akhavan¹,

Mousavi²,

Alibakhshi³

2016

Obstet Gynecol Cancer Res

View full text Add to dashboard Cite

Borderline ovarian tumors (BOT) consist of epithelial ovarian lesions that express cytological features of malignancy, but unlike malignant ovarian tumors, do not show obvious stromal invasion. The tumor incidence is between 1.8 and 4.8 per 100,000 females per year. The two major groups of BOT include serous BOT (S-BOT) and mucinous BOT (M-BOT). S-BOTs are divided into two categories: tumors limited to ovary and tumors spreading outside the ovary. M-BOTs are divided into two categories. The more common type is intestinal that constitutes 85% of cases and the second type is endocervical or Mullerian. Mullerian M-BOTs is bilateral in 40% of cases, while it is accompanied by pelvic endometriosis in 20-30% of patients. Microscopic examination by intraoperative frozen section is necessary because macroscopic view of ovarian tumors alone is not reliable. It is better to perform conservative surgery until the final report is ready in patients who wish to preserve their fertility. It is hard to differentiate them based on clinical characteristics. Values of tumor markers including CA125, CA19-9 and CEA in diagnosis of BOT are confirmed. Standard treatment of BOT is surgery as is the case with invasive epithelial ovarian cancer. In the majority of patients referred for BOT, since there is no suspicion of malignancy, staging is not performed. In these cases, making decision to repeat surgery and staging depend on factors such as the type of histology, abdominal exploration results in the previous surgery and probability of the presence of residual tumor.

show abstract

Hormone replacement therapy in gynecologic cancer survivors: Why not?

Cited by 43 publications

References 65 publications

Iatrogenic Menopause After Treatment for Cervical Cancer

Iatrogenic Menopause After Treatment for Cervical Cancer

National consensus on the management of patients in menopause

Diagnosis and Management of Borderline Ovarian Tumor Based on the Iranian Guidelines

Contact Info

Product

Resources

About